EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aytu BioPharma's EBITDA for the
three
months ended in Dec. 2023 was $4.54 Mil. Aytu BioPharma's Revenue for the
three
months ended in Dec. 2023 was $22.93 Mil. Therefore, Aytu BioPharma's EBITDA margin for the quarter that ended in Dec. 2023 was 19.81%.
Aytu BioPharma EBITDA Margin % Historical Data
The historical data trend for Aytu BioPharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aytu BioPharma's EBITDA Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's EBITDA Margin % falls into.
Aytu BioPharma EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Aytu BioPharma's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aytu BioPharma EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Aytu BioPharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Aytu BioPharma (Aytu BioPharma) Business Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AYTU has been successfully added to your 